Medication info

Fosidicm Extended Release Tablet 10/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
International Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, egg-shaped film-coated tablets
Packaging
30 tablets per bottle
Approval status
Approval withdrawn

MFDS item code 202204069 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.17. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no previous experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy alone: When used as initial therapy in patients with no previous experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. To reduce gastrointestinal adverse reactions to metformin, adjust the dose gradually. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because such a change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Metformin is excreted through the kidneys, and renal function is likely to decline in older adults; therefore, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Ingredients

Manufacturer
International Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • blood sugar control issues
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in adult patients with Type 2 diabetes. The combination of dapagliflozin and metformin effectively manages blood sugar levels. Attention should be paid to the impact on the occurrence of cardiovascular events, particularly in patients whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors. This medication is used to improve blood sugar control in diabetes patients.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no previous experience of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy alone: When used as initial therapy in patients with no previous experience of antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. To reduce gastrointestinal adverse reactions to metformin, adjust the dose gradually. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, the dose of this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from another antihyperglycemic agent. Because such a change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg daily. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Metformin is excreted through the kidneys, and renal function is likely to decline in older adults; therefore, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Precautions

This medication is used to control blood sugar levels and should not be administered to patients with poor kidney function. While rare, serious lactic acidosis can occur while on this medication. If symptoms such as malaise, muscle pain, difficulty breathing, or abdominal pain appear, it is important to consult a doctor immediately. Hypoglycemia may occur when used with other diabetes medications, so careful monitoring of blood sugar levels is required. It is advisable not to take this medication if you are experiencing acute infections, dehydration, heart disease, or liver dysfunction. When undergoing examinations using iodine-based contrast agents, you should discontinue this medication at least 48 hours before the test and resume only after confirming that kidney function is normal. Pregnant or breastfeeding women should not use this medication, and women who may become pregnant should also avoid it. Elderly patients are at higher risk for decreased kidney function, so kidney function tests should be performed prior to administration, and regular monitoring should continue during treatment. Excessive alcohol consumption should be avoided while taking this medication, as alcohol can increase the risk of lactic acidosis. Patients with a risk of decreased fluid volume or low blood pressure should carefully monitor blood pressure and fluid status while on this medication. This medication may increase the risk of genital infections and urinary tract infections, so if any infection symptoms appear, prompt treatment should be sought. If blood sugar control fails or abnormal symptoms develop, consult healthcare professionals immediately for appropriate action. Regular blood tests and monitoring of vitamin B12 levels should be performed while taking this medication to check for abnormalities. Caution is advised while driving or operating machinery due to possible dizziness. This medication should be kept out of reach of children and stored in its original container to maintain quality.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • glans penis inflammation
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • hypovolemia
  • thirst
Show 83 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant neoplasm of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • sialadenopathy
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular syndrome
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a tightly closed container to protect it from exposure to air or moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature. This helps preserve the medication's effectiveness and prevent deterioration.

Appearance and packaging

Appearance

Pink, bilaterally convex, egg-shaped film-coated tablets

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.